Clinical Trial Update: Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining the combination of pirtobrutinib and venetoclax with measurable residual disease (MRD) detection for previously untreate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Mayo Clinic | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING